Summary Adult skeletal muscle stem cells (MuSCs) are important for muscle regeneration and constitute a potential source of cell therapy. However, upon isolation, MuSCs rapidly exit quiescence and lose transplantation potency.

Tubastatin A is a powerful and selective pharmacological tool for investigating the role of HDAC6 and α-tubulin acetylation in a wide range of biological processes.

In this article, Arjona et al. show that TubA, an HDAC6 inhibitor, can inhibit primary cilium resorption and preserve MuSC quiescence and stem cell potency ex vivo.

Many of these epigenetic regulators are dysregulated to affect cell homeostasis pathways in diseased cells and tissues. Because histone marks have stable covalent structures, they can be inherited during cell division and DNA duplication and serve as disease markers.

The trans-stimulation potency of 40 selected compounds for already known specific substrates ( [3H]-clonidine) were determined and compared in the human brain endothelial cell line hCMEC/D3.

To confirm that Tuba statin A is active in your specific cell model, a series of validation experiments are recommended. These assays directly measure enzyme inhibition, the immediate downstream substrate modification, and the broader impact on cell health.

In 661W cells HDAC6 inhibition by the specific inhibitor tubastatin A (TST) led to the acetylation of α-tubulin, which is a major substrate for HDAC6.

Despite its cytoprotective roles, HDAC6 has emerged as a therapeutic target due to its involvement in multiple pathological pathways and age-related disorders.

Tubastatin A is selective at all isozymes except HDAC8 and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately 57-fold selectivity.

Antiproliferative activity against human HEL cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay